Pharamceutical Microbiology Conference

Pharmaceutical Parallel Trade in the European Union is a large and growing phenomenon.

Different regulatory regimes for pharmaceuticals result in significant differences in pharmaceutical prices across countries. These prices make it profitable for Parallel Trade to take place in addition to PT reaching a significant proportion of total national pharmaceutical expenditure in many European countries, particularly those with high pharmaceutical prices such as UK, Germany, the Netherlands and Sweden. But the issue of pharmaceutical Parallel Trade continues to generate controversy among stake holders and has become an issue of intense debate in the global trading system.
 

Europe’s leading Parallel Trade Conference will focus on assessing pricing strategies and the impact of parallel trade on the generics market and vice versa. In addition, there will be three open floor round table discussions drawing attention to the ongoing debate; is parallel trade justified? Stakeholder engagement and competition law effects will be discussed, in addition to a breakfast briefing on assessing data collection… and that’s just to start with.

Benefits of Attending

• Hear from those at the heart of Parallel Trade on the core concerns affecting you. Addressing the challenges are Eric Noehrenberg, Janice Haigh and Richard Freudenberg
• Germany are the industry leaders in this field, hear from IGES on Parallel Trade in Germany and what the influencing factors are and analysing the market
• Enhance supply chain protection and patient safety with an update on the Falsified Medicines Directive
• Case study sessions on best practices and implementation, in addition to three round table discussions will generate debate, don’t miss out!

Who Should Attend

Directors, Managing Directors, Leaders, Head of:
Research and Development, Market Access, Pricing and Reimbursement, Commercial, Supply Chain Policy, Finance, Anti-Counterfeiting, Business Analysts, Distribution, Legal Affairs

Consultants of Advisors working in Health Economics, Business Development, Supply Chain Security in addition to Pharmacists. 

Companies include: 
 

InnoPeritus; Abbott Healthcare products; Allergan Ltd; Amdipharm Mercury Company Limited; Amgen ; Amgen BV; Amgen Europe BV; Amgen Ltd; Amgen Swizerland A G; Arnold and Porter; Astellas Pharma Europe; AstraZeneca; Biogen IDEC International GmbH; Boehringer-Ingelheim; Bristol Meyers Squibb; Chiesi Farmaceutici SpA; Decahedron Ltd.; Delfarma; Domino Uk Limited; Dusseldorf Institute for Competition Economics; Eli Lilly & Co; European Alliance for Access to Safe Medicines; European Commission; European Generic Medicines Association; Genzyme Corporation; Gilead Sciences Europe Ltd; Grünenthal GmbH; GSK; HOLLISTER, INC.; IMS Health; Johnson & Johnson Pharmaceutical; Justpharmareports; Kantar Health GmbH; Kohlpharma GmbH; LEO Pharma; Leo Pharmaceutical Products Ltd. A/S; Merck Sharp and Dohme Israel; MPA Business Services Ltd ; None; Novartis; Novartis (Hellas) SACI; Novartis Pharma AG; Novo Nordisk; Panhellenic Pharmacists Association; Quintiles (UK) Ltd; Shire Pharmaceuticals Group Plc; Teva UK; White & Case LLP;

Patient safety is first and foremost when it comes to the implementation of the Anti-Counterfeit Directive and this will be addressed. What will follow is assessing the repackaging and re-boxing of products. Further topics to be evaluated include case studies on the implementation of best practices and the outcomes to be reviewed on parallel trade, are they positive or negative?
 

The note to end on will be… What’s the future of Parallel Trade?